Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Health Care Costs Could Be Cut By Routine Diabetes Screenings
Screening adults for diabetes could result in significant cost-savings for health care systems compared to the costs of not screening individuals at all. Don't forget to buy zoloft online no prescription.

New Regulatory Opportunities For The EU: Rules For How Rules Are To Be Followed
The European Union readily brings to mind rules and regulations regarding everything from the shape of a cucumber to the generation of statistics. The EU"s formal regulations consist of more than 300,000 legal documents. However, a new dissertation in business studies at Stockholm University shows that, in practice, the regulation of the EU is much more comprehensive than that.

generic viagra online


News of the day
New Survey Shows Americans Strongly Support Guaranteed Dental Coverage In Healthcare Reform
Nearly 2 in 3 U.S. adults (63%) think that it is important that dental coverage is part of an overall health reform package, and 40 percent say it is very important, according to a new public opinion survey commissioned by Oral Health America. The survey, sponsored by the Dental Trade Alliance Foundation, and conducted by Harris Interactive(R), was released today at the launch of National Smile Month, the largest independent international campaign promoting good dental care including brushing, regular dental visits, and healthy food choices as well as the need for effective oral healthcare policies.
Sexual Health

Agendia To Present Multiple Predictive And Prognostic Studies On Breast And Colorectal Cancers At ASCO Annual Meeting

Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple studies at the American Society of Clinical Oncology Annual Meeting, May 29 - June 2, 2009, in Orlando, Florida. The study results further underpin the broad predictive and prognostic power of Agendia"s breast cancer recurrence test MammaPrint(R) and highlight promising data on Agendia"s new colon cancer recurrence test, ColoPrint(TM). Visitors can meet the Agendia team in booth #2014 and study results will be discussed at the following sessions: Date: Saturday, May 30, 2009 ORAL PRESENTATION Abstract #512 Time: 5:00PM - 5:15PM Location: Level 2, West Hall D1 The 70-gene profile and chemotherapy benefit in 1,600 breast cancer patients R. A. Bender, M. Knauer, E. J. Rutgers, A. M. Glas, F. A. de Snoo, S. C. Linn, L. J. Van "t Veer Date: Saturday, May 30, 2009 ORAL PRESENTATION Abstract # LBA515 Time: 3:00PM - 6:00PM Location: Level 2, West Hall D1 Breast cancer molecular profiles predict tumor response of neoadjuvant Doxorubicin and Taxol, the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) L. J. Esserman, C. Perou, M. Cheang, A. DeMichele, L. Carey, L. J. van "t Veer, J. Gray, E. Petricoin, K. Conway, D. Berry, I-Spy Investigators Date: Saturday, May 30, 2009 POSTER PRESENTATION Abstract #6570 Time: 2:00PM - 6:00PM Location: Level 2, West Hall C Cost effectiveness of targeting chemotherapy with the 70-gene prognostic signature in early stage breast cancer (ESBC) patients K. B. Tong, E. Chen, G. Brink, R. Bender, F. de Snoo, J. Malin Date: Sunday, May 31, 2009 POSTER DISCUSSION Abstract #535 Time: 8:00AM - 12:00PM Location: Level 2, West Hall D1, W240A Outcome prediction by the 70-gene profile in the context of the National Comprehensive Cancer Network (NCCN) guideline F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers, A. M. Glas, S. C. Linn, L. J. Van "t Veer Date: Sunday, May 31, 2009 POSTER PRESENTATION Abstract #4036 Time: 8:00 AM - 12:00 PM Location: Level 2, West Hall C Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients A. M. Glas, P. Roepman, R. Salazar, G. Capella, V. Moreno, J. Westerga, P. J. Kuppen, I. Simon, L. J. Van "t Veer, R. Tollenaar Date: Sunday, May 31, 2009 POSTER DISCUSSION Abstract #518 Time: 8:00AM - 12:00PM Location: Level 2, West Hall D1, W240A Early determination of metastatic potential in breast cancer: the 70-gene signature in small tumors M. Knauer, S. Mook, V. Retç¨l, M. Kok, J. Wesseling, A. M. Glas, E. J. Rutgers, L. J. van "t Veer, S. C. Linn Date: Monday, June 01, 2009 POSTER PRESENTATION Abstract #11083 Time: 1:00PM - 5:00PM Location: Level 2, West Hall C Combining multi-gene profiling of molecular subtypes with the 70-gene profile for classification of breast cancer L. Stork-Sloots, O. Krijgsman, P. Roepman, F. A. de Snoo, R. A. Bender, A. M. Glas About MammaPrint(R) MammaPrint is the first "in vitro diagnostic multivariate index assay" (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests. All MammaPrint tests are conducted in Agendia"s CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process. Agendia B.V.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009